Patient-specific monocyte-derived microglia as a screening tool for neurodegenerative diseases
1Mental Health and Neuroscience, QIMR Berghofer Medical Research Institute; School of Biomedical Science, The University of Queensland, Brisbane, QLD, Australia.
Abstract:
Microglia, the main driver of neuroinflammation, play a central role in the initiation and exacerbation of various neurodegenerative diseases and are now considered a promising therapeutic target. Previous studies on in vitro human microglia and in vivo rodent models lacked scalability, consistency, or physiological relevance, which deterred successful therapeutic outcomes for the past decade. Here we review human blood monocyte-derived microglia-like cells as a robust and consistent approach to generate a patient-specific microglia-like model that can be used in extensive cohort studies for drug testing. We will highlight the strength and applicability of human blood monocyte-derived microglia-like cells to increase translational outcomes by reviewing the advantages of human blood monocyte-derived microglia-like cells in addressing patient heterogeneity and stratification, the basis of personalized medicine.
Insights
Human microglia-like cells derived from blood monocytes offer a scalable and consistent model for studying neuroinflammation and neurodegenerative diseases. This patient-specific approach enhances drug testing and advances personalized medicine for neurological conditions.
Area of Science:
- Neuroscience
- Immunology
- Genetics
Background:
- Microglia are key drivers of neuroinflammation in neurodegenerative diseases.
- Existing in vitro and in vivo models lack scalability, consistency, and physiological relevance.
- This has hindered therapeutic development for neurological conditions over the past decade.
Purpose of the Study:
- To review human blood monocyte-derived microglia-like cells as a robust model.
- To highlight their applicability in drug testing and cohort studies.
- To emphasize their role in advancing personalized medicine for neurodegenerative diseases.
Main Methods:
- Review of existing literature on human blood monocyte-derived microglia-like cells.
- Analysis of the advantages of these cells for patient-specific modeling.
- Evaluation of their potential for addressing patient heterogeneity and stratification.
Main Results:
- Human blood monocyte-derived microglia-like cells provide a scalable and consistent platform.
- These cells offer greater physiological relevance compared to traditional models.
- They enable patient-specific modeling crucial for personalized medicine.
Conclusions:
- Human blood monocyte-derived microglia-like cells represent a significant advancement in modeling neurodegenerative diseases.
- This approach improves the translational potential of drug discovery.
- It facilitates personalized medicine strategies by accounting for patient heterogeneity.
